Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 26, Issue 21, Pages 3598-3606Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2008.16.1323
Keywords
-
Categories
Funding
- NCI NIH HHS [U10 CA037517, CA 27469, U10 CA027469, CA 37517] Funding Source: Medline
Ask authors/readers for more resources
Purpose We hypothesized that common polymorphisms in excision repair cross-complementation group 1 (ERCC1), involved in nucleotide excision repair of platinum-induced damage, would be associated with progression-free survival (PFS) and overall survival (OS) in women with optimally resected, stage III epithelial ovarian cancer (EOC) treated with cisplatin and paclitaxel (C+P). Patients and Methods Single nucleotide polymorphism analysis was carried out by direct pyrosequencing at two sites (codon 118 and C8092A) in ERCC1 in leukocyte DNA from women who participated in the Gynecologic Oncology Group (GOG) phase III protocol-172 and were randomly assigned to intraperitoneal or intravenous C+P. Results ERCC1 genotyping was performed in 233 of the 429 women who participated in GOG-172. The genotype distribution at codon 118 was 17% with C/C, 43% with C/T, and 40% with T/T, and the genotype distribution at C8092A was 56% with C/C, 37% with C/A, and 7% with A/A. Adjusted Cox regression analysis revealed that the codon 118 polymorphism in ERCC1 was not significantly associated with disease progression or death. Women with the C8092A C/A or A/A genotypes compared with the C/C genotype had an increased risk of disease progression (hazard ratio [HR] = 1.44; 95% CI, 1.06 to 1.94; P=.018) and death (HR = 1.50; 95% CI, 1.07 to 2.09; P=.018). Median PFS and OS were 6 and 17 months shorter for women with the C8092A C/ A or A/ A genotypes versus the C/C genotype, respectively. Conclusion Although the ERCC1 codon 118 polymorphism does not seem to be associated with clinical outcome, the C8092A polymorphism was an independent predictor of PFS and OS in women with optimally resected EOC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available